Employer Drug Coverage 2027 | How Costs Are Changing Benefit Plans

Rising Healthcare Costs Trigger Employer Action

US employers are preparing to remove coverage for GLP-1 weight-loss medications as part of their 2027 health strategy. New data from the Business Group on Health indicates that corporations expect a 9.2% jump in overall healthcare expenses by 2027. This financial pressure has forced a shift in policy, with 14% of surveyed employers stating they plan to drop or have already discontinued coverage for these drugs.

Pharmacy spending currently accounts for one-quarter of total employer healthcare costs. With those expenses projected to climb by 12% next year, finance departments are reviewing benefit packages for potential savings. The trend follows a period of rapid adoption for these treatments, which two-thirds of employers now report are used more frequently by their staff.

Shifting Benefits and Management Strategies

The move away from covering weight-loss drugs marks a distinct change in employer behavior. In 2025, 72% of employers provided coverage for these treatments. That share dropped to 60% in 2026. This downward trend suggests that many companies are no longer willing to absorb the high long-term costs associated with providing these medications to their workforces.

Ellen Kelsay, president of the Business Group on Health, described the current situation as a difficult reality for employers. She noted the struggle companies now face regarding accurate budgeting and financial forecasting for their benefit programs. Many are looking at their overall health strategy to identify where they can reduce waste and maintain better control over their bottom line.

The Path Toward Value-Based Care

Despite the reduction in coverage, the focus for many leadership teams has shifted toward demanding better results from their medical vendors. Kelsay emphasized the need for a more direct approach when dealing with partners that provide health benefits to employees. Holding these vendors accountable for specific outcomes remains a priority as companies try to balance employee needs with rising costs.

Industry analysts often point to the high price of GLP-1 treatments as a barrier to sustained employer funding. Without a significant reduction in the list price for these drugs, more companies will likely choose to exit coverage plans to protect their profit margins.

This shift highlights the tension between providing access to modern medicine and managing corporate health budgets. As 2027 approaches, industry observers will watch to see if these coverage gaps lead to an increase in out-of-pocket costs for individual workers or if new, lower-cost alternatives enter the market. The broader impact on workplace health and insurance structures remains uncertain as companies weigh the value of these medications against the reality of double-digit cost increases.